C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 120 filers reported holding C4 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $56,172 | -88.1% | 30,200 | -82.4% | 0.00% | -100.0% |
| Q2 2023 | $471,900 | +7.0% | 171,600 | +22.2% | 0.00% | 0.0% |
| Q1 2023 | $440,956 | -44.5% | 140,432 | +4.3% | 0.00% | -66.7% |
| Q4 2022 | $794,577 | -18.8% | 134,674 | +20.7% | 0.00% | 0.0% |
| Q3 2022 | $978,000 | +22.4% | 111,556 | +5.3% | 0.00% | +50.0% |
| Q2 2022 | $799,000 | -26.0% | 105,929 | +138.0% | 0.00% | 0.0% |
| Q1 2022 | $1,080,000 | -24.6% | 44,500 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $1,433,000 | -27.9% | 44,500 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $1,988,000 | +18.1% | 44,500 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $1,684,000 | – | 44,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $14,402,000 | 1.72% |
| Soleus Capital Management, L.P. | 1,441,513 | $12,642,000 | 1.72% |
| Nextech Invest Ltd. | 375,857 | $3,296,000 | 1.06% |
| RTW INVESTMENTS, LP | 2,819,472 | $24,727,000 | 0.57% |
| ArrowMark Colorado Holdings LLC | 5,091,975 | $44,657,000 | 0.55% |
| WASATCH ADVISORS LP | 5,934,476 | $52,045,000 | 0.36% |
| HARBOR CAPITAL ADVISORS, INC. | 25,470 | $223,000 | 0.20% |
| Perceptive Advisors | 766,231 | $6,720,000 | 0.20% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 606,721 | $5,321,000 | 0.08% |
| Virtus ETF Advisers LLC | 19,305 | $169,000 | 0.07% |